Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial

[1]  M. Landray,et al.  Empagliflozin in Patients with Chronic Kidney Disease , 2022, The New England journal of medicine.

[2]  J. McMurray,et al.  Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF). , 2022, Circulation.

[3]  S. Ringgaard,et al.  Evaluation of renal oxygenation by BOLD-MRI in high-risk patients with type 2 diabetes and matched controls. , 2022, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  Siyi Gong,et al.  Canagliflozin could improve the levels of renal oxygenation in newly diagnosed type 2 diabetes patients with normal renal function. , 2021, Diabetes & metabolism.

[5]  J. McMurray,et al.  Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. , 2021, The lancet. Diabetes & endocrinology.

[6]  P. Groop,et al.  Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial , 2021, EClinicalMedicine.

[7]  S. Vinogradov,et al.  Impact of sodium glucose linked cotransporter‐2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus , 2021, Physiological reports.

[8]  M. Nieuwdorp,et al.  Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial , 2021, Diabetes, obesity & metabolism.

[9]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[10]  W. Willett,et al.  Coffee, Caffeine, and Health. , 2020, The New England journal of medicine.

[11]  M. Burnier,et al.  Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo‐Controlled Trial , 2020, Journal of the American Heart Association.

[12]  R. Gómez Huelgas,et al.  Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents , 2020, International journal of clinical practice.

[13]  G. Laverman,et al.  The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors? , 2020, Kidney international.

[14]  V. Vallon,et al.  The tubular hypothesis of nephron filtration and diabetic kidney disease , 2020, Nature Reviews Nephrology.

[15]  C. M. Sørensen,et al.  Glucagon-Like Peptide-1 Receptors in the Kidney: Impact on renal autoregulation. , 2019, American journal of physiology. Renal physiology.

[16]  S. Francis,et al.  Consensus-based technical recommendations for clinical translation of renal ASL MRI , 2019, Magnetic Resonance Materials in Physics, Biology and Medicine.

[17]  Michael E. Hall,et al.  Consensus-based technical recommendations for clinical translation of renal BOLD MRI , 2019, Magnetic Resonance Materials in Physics, Biology and Medicine.

[18]  F. Geurts,et al.  The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. , 2019, Kidney international.

[19]  J. Coresh,et al.  Measured and estimated glomerular filtration rate: current status and future directions , 2019, Nature Reviews Nephrology.

[20]  B. Geist.  Calculation of GFR via the Slope-Intercept Method in Nuclear Medicine , 2019, Glomerulonephritis and Nephrotic Syndrome.

[21]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[22]  E. Gutmark,et al.  Impaired aortic distensibility and elevated central blood pressure in Turner Syndrome: a cardiovascular magnetic resonance study , 2018, Journal of Cardiovascular Magnetic Resonance.

[23]  M. Stuber,et al.  Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease. , 2018, Kidney international.

[24]  Frank B. Hu,et al.  Global aetiology and epidemiology of type 2 diabetes mellitus and its complications , 2018, Nature Reviews Endocrinology.

[25]  B. Zinman,et al.  How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial , 2017, Diabetes Care.

[26]  M. Stuber,et al.  Reduction of cortical oxygenation in chronic kidney disease: evidence obtained with a new analysis method of blood oxygenation level-dependent magnetic resonance imaging , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  R. Vettor,et al.  SGLT2 Inhibitors and the Diabetic Kidney , 2016, Diabetes Care.

[28]  J. Holst,et al.  Short‐term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial , 2016, Diabetes, obesity & metabolism.

[29]  A. Layton,et al.  Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron. , 2016, American journal of physiology. Renal physiology.

[30]  J. Holst,et al.  Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy. , 2016, American journal of physiology. Endocrinology and metabolism.

[31]  Wei Li,et al.  Multi-Parametric Evaluation of Chronic Kidney Disease by MRI: A Preliminary Cross-Sectional Study , 2015, PloS one.

[32]  N. Buus,et al.  Evaluation of Renal Blood Flow and Oxygenation in CKD Using Magnetic Resonance Imaging. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  F. Palm,et al.  Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. , 2015, American journal of physiology. Renal physiology.

[34]  E. Porrini,et al.  Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. , 2015, The lancet. Diabetes & endocrinology.

[35]  M. Stuber,et al.  Determinants of Renal Tissue Oxygenation as Measured with BOLD-MRI in Chronic Kidney Disease and Hypertension in Humans , 2014, PloS one.

[36]  M. Stuber,et al.  Effect of dark chocolate on renal tissue oxygenation as measured by BOLD-MRI in healthy volunteers. , 2013, Clinical nephrology.

[37]  Fang Liu,et al.  Noninvasive evaluation of renal oxygenation in diabetic nephropathy by BOLD-MRI. , 2012, European journal of radiology.

[38]  P. Thelwall,et al.  Non-invasive investigation of kidney disease in type 1 diabetes by magnetic resonance imaging , 2011, Diabetologia.

[39]  Zhen J. Wang,et al.  Blood oxygen level‐dependent (BOLD) MRI of diabetic nephropathy: Preliminary experience , 2011, Journal of magnetic resonance imaging : JMRI.

[40]  J. López-Novoa,et al.  Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives. , 2010, Pharmacology & therapeutics.

[41]  M. Burnier,et al.  Effect of Sodium Loading/Depletion on Renal Oxygenation in Young Normotensive and Hypertensive Men , 2010, Hypertension.

[42]  J. Ware,et al.  Applied Longitudinal Analysis , 2004 .

[43]  C. Orphanides,et al.  Progressive renal disease: the chronic hypoxia hypothesis. , 1998, Kidney international. Supplement.